FOX CHASE CANCER CENTER

Fox Chase Cancer Center researchers found that neoadjuvant chemotherapy followed by local excision achieved negative margins in 79% of patients with node-negative low rectal cancer, potentially avoiding permanent colostomies.

Phase I/II trial demonstrates that patients with metastatic renal cell carcinoma who respond well to nivolumab-axitinib combination can safely pause treatment after 2 years, with five out of six previously treated patients maintaining progression-free status.

Fox Chase Cancer Center's RETAIN-2 trial demonstrates promising results using combined ddMVAC chemotherapy and nivolumab immunotherapy for muscle-invasive bladder cancer treatment.

A randomized trial at MD Anderson Cancer Center demonstrates that integrating smoking cessation services within lung cancer screening programs achieved 37.1% abstinence rates at 3 months, significantly outperforming standard quitline referrals.

Real-world analysis shows patients receiving epcoritamab for DLBCL travel nearly twice the distance (4,486 miles) compared to glofitamab (2,243 miles) over 12 months of treatment.

The Ohio State University Cancer Center's automated informatics program has achieved a 21.9% increase in biosimilar utilization while streamlining prior authorization processes, earning an Innovator Award at ACCC 2024.

A pioneering pilot program at Fox Chase Cancer Center demonstrated significant improvements in palliative care knowledge and confidence among hematology/oncology fellows through an integrated longitudinal training approach.

A phase II trial of biomarker-driven treatment for muscle-invasive bladder cancer (MIBC) demonstrated a 2-year metastasis-free survival (MFS) rate exceeding 70%.

The AUA 2024 meeting showcased promising advancements in male contraceptive research, including hormonal gels and nonhormonal approaches, addressing the growing need for expanded contraceptive options following the Dobbs decision.

Fox Chase Cancer Center's Study Activation Unit (SAU) has significantly reduced the median time to new study activation by 182 days, surpassing their initial goal.